Leading CBD Provider Reports 255% Revenue Growth
November 27th, 2017
Exclusive, News, Top News
The cannabis industry is one of the most attractive areas of the market following the legalization of medical and recreational marijuana throughout a large part of North America. In the U.S., 44 states and three territories have passed cannabis laws to some degree and recreational cannabis has been legalized in eight states including the District of Columbia. Analysts expect North American cannabidiol (CBD) sales will surpass $1 billion by 2020.
In this article, we will look at why Medical Marijuana Inc. (OTC Pink: MJNA) represents a compelling opportunity in the space with strong growth during the third quarter and diversified operations across many geographies and subsets of the cannabis industry.
Strong Growth in Revenue & Profitability
Medical Marijuana Inc. reported third quarter gross revenue that increased 255% to $7,783,297. While the company didn’t break down its revenue, management cited investments in subsidiaries and continued international expansion and product development as key drivers of the growth. HempMeds®, in particular, has continued to see strong demand from international markets like Mexico and Brazil where its products can be imported for medical use.
On the bottom line, the company’s gross profit increased 297% to $5,034,464, suggesting some margin expansion during the quarter. Management reported that its net loss narrowed by 30% to $2,959,173 as it moves closer to a breakeven point on a net income basis. When accounting for notes receivable, inventories, and other factors, the company reported just over $1 million in net cash used in operations, which may be a more accurate portrayal of profitability.
“We are excited to announce such outstanding leaps in growth and success this quarter,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus in a press release. “We believe that with these record-breaking revenue numbers, we have the capacity to make 2018 the most profitable year the company has ever seen. We are currently spending on international expansion and research efforts which should pay long-term dividends for shareholders.”
Strong Investment Performance
Medical Marijuana Inc.’s investment portfolio continues to produce strong results. Last quarter, the company reported nearly $80 million in net cash provided by investment activities. Total assets reached $345,388,650 during the quarter, compared to just $13,170,561 in total liabilities, which translates to total equity of $334,136,047. The company’s portfolio consists of AXIM Biotechnologies and Kannalife Sciences.
The company’s flagship investment is its roughly $150 million stake in AXIM Biotechnologies Inc. (OTCQB: AXIM). Over the past quarter, AXIM Biotech entered into a clinical study agreement with the University of British Columbia in Canada to begin clinical trials with its CanChew Plus® CBD chewing gum to treat drug-induced psychosis in adults. It also entered into a services agreement with an Israeli CRO to begin a proof of concept study of its CBD chewing gum in patients with restless leg syndrome.
The company’s 16.7% stake in Kannalife Sciences also continues to demonstrate strong potential. With two licenses from the National Health Institute for use of its patent on cannabinoids as antioxidants and neuroprotectants, the company has focused on treating hepatic encephalopathy and chronic traumatic encephalopathy. Recently, Kannalife presented scientific data from its clinical trials at the Annual ICRS Symposium on Cannabinoids.
Medical Marijuana Inc. (OTC Pink: MJNA) offers investors exposure to the rapidly growing cannabis industry through a combination of CBD-based products and clinical research. With a market capitalization of about $310 million, the company trades at less than its shareholders’ equity with strong triple-digit top- and bottom-line growth rates. Investors interested in the space may want to consider the stock for their portfolios.
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.